




# European Pharma Market Outlook to 2022


Size of the market in EU-5 set to **grow by 25%** between 2017-2022 with a CAGR of 4.5% over this period

EU-5 accounts for **69% of European pharma market** in 2022

Germany is forecast to have highest increase in market value at **€9.7bn**



## Marketed vs. R&D: Historical and Forecast sales to 2022 (€m)



By 2022, products currently in R&D will account for **13% of sales in Europe**

■ Marketed ■ R&D

## Marketed Products

Xarelto is set to be the **biggest selling drug in Europe** in 2022

Around **34% of the anti-coagulant product's sales** set to come from Germany

### Top selling marketed products in 2022

Product	€m
1. Xarelto	€2,820
2. Eliquis	€2,249
3. Revlimid	€2,195
4. Imbruvica	€1,830
5. Humira	€1,674

## R&D Focus


Sanofi's R&D product **Dupixent** is forecast to have the **highest sales** in 2022

Dupixent, currently in Phase III, is **set to launch in 2017**


### Top selling R&D products in 2022

Product	€m
1. Dupixent	€955
2. Bictgravir/F/TAF	€776
3. Ocrevus	€691
4. Imfinzi	€504
5. Cevira	€499

## Key marketed product forecasts to 2022



## Key R&D product forecasts to 2022





Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

**EvaluatePharma**<sup>®</sup> delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](#)

**EvaluateMedTech**<sup>®</sup> sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](#)

**EvaluateClinical Trials**<sup>®</sup> delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](#)

**EP Vantage** an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](#)

**Evaluate Custom Services** provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

[www.evaluate.com](http://www.evaluate.com)

---

**Evaluate Headquarters**

Evaluate Ltd.  
11-29 Fashion Street  
London E1 6PX  
United Kingdom  
T +44 (0)20 7377 0800  
F +44 (0)20 7539 1801

**Evaluate Americas**

EvaluatePharma USA Inc.  
15 Broad Street, Suite 401  
Boston, MA 02109  
USA  
T +1 617 573 9450  
F +1 617 573 9542

**Evaluate APAC**

Evaluate Japan KK  
Akasaka Garden City 4F  
4-15-1 Akasaka, Minato-ku  
Tokyo 107-0052  
Japan  
T +81 (0)80 1164 4754